Medtronic plc (MDT) Gross Margin: 65.02%
Is Medtronic plc’s gross margin high or low?
Medtronic plc's gross margin of 65.02% is in line with its 5-year average of 65.75%, near the low end of its 5-year range (65.02%–67.98%).
The gross margin for Medtronic plc (MDT) is 65.02% as of Wednesday, June 10, 2026. It is below its 12-month average by 0.23% (65.17%).
MDT Gross Margin Chart
MDT Average Gross Margin Chart
MDT Current vs Average Gross Margin Chart
MDT Gross Margin Metrics
GROSS MARGIN
65.02%
GROSS MARGIN AVG TTM
65.17%
GROSS MARGIN AVG 3Y
65.34%
GROSS MARGIN AVG 5Y
65.75%
GROSS MARGIN AVG 10Y
67.16%
GROSS MARGIN AVG 15Y
69.21%
GROSS MARGIN AVG 20Y
70.56%
CURRENT VS TTM AVG
-0.23%
CURRENT VS 3Y AVG
-0.49%
CURRENT VS 5Y AVG
-1.12%
CURRENT VS 10Y AVG
-3.18%
CURRENT VS 15Y AVG
-6.05%
CURRENT VS 20Y AVG
-7.85%
MDT Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medtronic plc (MDT) | — | 65.02% | 65.17% | 65.34% | 65.75% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 86.28% | 85.57% | 86.56% | 87.08% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 68.75% | 62.23% | 59.55% | 57.82% |
| Elevance Health Inc. (ELV) | $87.43B | 23.16% | 26.70% | 26.59% | 26.68% |
| CVS Health Corporation (CVS) | $125.16B | 13.87% | 13.78% | 14.92% | 15.96% |
| Cigna Corporation (CI) | $78.25B | 9.30% | 9.98% | 11.47% | 12.36% |
| Danaher Corporation (DHR) | $130.25B | 60.68% | 60.22% | 59.98% | 59.48% |
| Regeneron Pharmaceuticals, Inc. (REGN) | $62.59B | 84.55% | 85.74% | 85.09% | 84.57% |
| Pfizer Inc. (PFE) | $146.36B | 69.35% | 68.05% | 62.23% | 63.06% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 66.29% | 66.73% | 66.82% | 67.04% |
Gross Margin Analysis
Gross Margin
65.0%
(Revenue - COGS) / Revenue
Medtronic plc Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medtronic plc Gross Margin FAQ
- What is the gross margin for Medtronic plc (MDT)?
- The gross margin for MDT stock is 65.02%.
- Is Medtronic plc's gross margin high or low?
- Medtronic plc's gross margin of 65.02% is in line with its 5-year average of 65.75%, near the low end of its 5-year range (65.02%–67.98%).
- What is the TTM average gross margin for Medtronic plc (MDT)?
- The TTM average gross margin for MDT stock is 65.17%.
- What is the 3Y average gross margin for Medtronic plc (MDT)?
- The 3Y average gross margin for MDT stock is 65.34%.
- What is the 5Y average gross margin for Medtronic plc (MDT)?
- The 5Y average gross margin for MDT stock is 65.75%.
- What is the 10Y average gross margin for Medtronic plc (MDT)?
- The 10Y average gross margin for MDT stock is 67.16%.
- What is the 15Y average gross margin for Medtronic plc (MDT)?
- The 15Y average gross margin for MDT stock is 69.21%.
- What is the 20Y average gross margin for Medtronic plc (MDT)?
- The 20Y average gross margin for MDT stock is 70.56%.
Medtronic plc Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-04-24 | 65.02% |
| 2025-04-25 | 65.32% |
| 2024-04-26 | 65.34% |
| 2023-04-28 | 65.67% |
| 2022-04-29 | 67.98% |
| 2021-04-30 | 65.19% |
| 2020-04-24 | 67.41% |
| 2019-04-30 | 70.04% |
| 2018-04-30 | 69.73% |
| 2017-04-30 | 68.72% |
| 2016-04-30 | 68.29% |
| 2015-04-30 | 68.86% |
| 2014-04-30 | 74.52% |
| 2013-04-30 | 75.13% |
| 2012-04-30 | 75.97% |
| 2011-04-30 | 74.11% |
| 2010-04-30 | 74.67% |
| 2009-04-30 | 75.90% |
| 2008-04-30 | 74.50% |
| 2007-04-30 | 74.24% |
| 2006-04-30 | 75.07% |
| 2005-04-30 | 75.68% |
| 2004-04-30 | 75.21% |
| 2003-04-30 | 75.34% |
| 2002-04-30 | 74.22% |
| 2001-04-30 | 79.95% |
| 2000-04-30 | 79.66% |
| 1999-04-30 | 80.94% |
| 1998-04-30 | 102.99% |
| 1997-04-30 | 94.96% |
Related Metrics
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha